Elite Pharmaceuticals Inc (ELTP) stock
Close on Oct 19, 2026Market cap $281.77MP/E 5.0Yield –
Elite Pharmaceuticals Inc grew revenue 17.8% to $144.77M over the twelve months to Sep 30, 2026. Operating income fell 13.1% to $36.65M, moving the operating margin from 34.3% to 25.3%. Free cash flow was $8.72M, down 59.7% from a year earlier. At the latest close the market valued the company at $281.77M, 5.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $281.77M
- P/E ratio
- 5.0
- Price to sales
- 1.95
- Price to book
- 2.31
- Dividend yield
- –
- Free cash flow yield
- 3.09%
Fundamentals
- Revenue
- $144.77M
- Net income
- $60.28M
- EPS, diluted
- $0.05
- Free cash flow
- $8.72M
- Book value per share
- $0.11
- Diluted shares
- 1.12B
Trading
- Next earnings
- Nov 13, 2026 (estimated, during market hours)
- Previous close
- $0.25
- Open
- $0.25
- Day's range
- $0.24 – $0.26
- Volume
- 491,654
- Average volume (20 days)
- 794,396
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELTP | S&P 500 | Difference | ELTP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.3% | +0.6% | +0.7 pts | ||
| 3 months | -35.4% | +3.4% | −38.8 pts | ||
| Year to date | -48.9% | +13.3% | −62.1 pts | ||
| 1 year | -59.2% | +16.6% | −75.8 pts | ||
| 3 years | +150.8% | +86.4% | +64.4 pts | +35.9% | +23.1% |
| 5 years | +526.9% | +81.9% | +445.0 pts | +44.4% | +12.7% |
| 10 years | +79.1% | +318.9% | −239.7 pts | +6.0% | +15.4% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Elite Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Update
- Update
About Elite Pharmaceuticals
Pharmaceutical Preparations
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and manufactures generic pharmaceuticals and oral, controlled-release medications. Its product portfolio spans several therapeutic classes, including central nervous system stimulants, pain management treatments, bariatric medications, cardiovascular agents, muscle relaxants, antidepressants, and antimetabolites. The company's commercial offerings include generic formulations such as amphetamine tablets and capsules, lisdexamfetamine, phentermine, naltrexone, and opioid combination pain relievers. Elite operates primarily through manufacturing and product licensing activities. The company sells its pharmaceutical products directly and indirectly to wholesale distributors, and it also collaborates with commercial partners through licensing agreements.
Company profile, executives and historyElite Pharmaceuticals stock: common questions
What is Elite Pharmaceuticals's stock price?
ELTP closed at $0.25 on Oct 19, 2026, down 1.37% on the day.
What is Elite Pharmaceuticals's market cap?
Elite Pharmaceuticals was worth $281.77M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ELTP's P/E ratio?
ELTP trades at 5.0 times earnings, based on diluted earnings per share of $0.05 over the twelve months to Sep 30, 2026.
How much revenue does Elite Pharmaceuticals make?
Elite Pharmaceuticals reported revenue of $144.77M for the twelve months to Sep 30, 2026, up 17.8% from a year earlier.
Does Elite Pharmaceuticals pay a dividend?
No. Elite Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Elite Pharmaceuticals report earnings next?
Elite Pharmaceuticals is expected to report Q2 FY2027 results on Nov 13, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ELTP stock performed over the past year?
Including dividends, ELTP returned -59.2% over the past year, against +16.6% for the S&P 500.
Who are Elite Pharmaceuticals's competitors?
Companies most similar to Elite Pharmaceuticals by business, industry and size include ETON, KPTI, KMDA, HRTX, ZVRA.
See a number that looks wrong?